

DAFTAR PUSTAKA

1. Takatori M, Kamogawa A, Iwabuchi S, Moriyama N, Mizuguchi A, Sugai J. Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography. *Rinsho Byori*. 1990;38(1):71-75.
2. World Health Organization. Hepatitis B. In: *World Health Organization*.; 2022.
3. Muljono DH. Epidemiology of hepatitis B and C in Republic Indonesia. *Euroasian J Hepato-Gastroenterology*. 2017;7(1):55-59. doi:10.37506/ijfmt.v14i2.2851
4. Cai G, Chen Y, Li L, et al. Meta-Analysis of Risk Factors for Development of Liver Cirrhosis in Chronic Hepatitis B Patients. *Glob J Infect Dis Clin Res*. 2018;4(2):4-9.
5. Sharma B, John S. Hepatic Cirrhosis. In: *StatPearls Publishing, Treasure Island (FL)*. ; 2022:1-7. <https://www.ncbi.nlm.nih.gov/pubmed/29494026>
6. Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. *Clin Liver Dis*. 2021;17(5):365-370. doi:10.1002/cld.1061
7. Lovena A, Miro S, Padang MD. Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. *J Kesehatan Andalas*. 2017;100(1):5-12.
8. Lapelusa A, Hd D. Physiology, Hemostasis Issues of Concern Organ Systems Involved. In: *StatPearls Publishing, Treasure Island (FL)*. ; 2022.
9. Blanco A. Hemostasis. In: *Medical Biochemistry*. Academic press; 2017:781-789. doi:10.1016/B978-0-12-803550-4/00031-8
10. Rabia I, Sumana K, Sueajkumar BJ, et all. Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their

Management. National Library of Medicine. 2022.
doi: 10.7759/cureus.23785

11. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: Evidence and clinical consequences. *Blood*. 2010;116(6):878-885. doi:10.1182/blood-2010-02-261891
12. Jilani T. Tissue Plasminogen Activator Mechanism of Action. In: *StatPearls Publishing, Treasure Island (FL)*. ; 2022.
13. OKABE K, KATO I, SATO S. Clinical evaluation of tissue plasminogen activator (tPA) levels in patients with liver diseases. *Japanese Soc Gastroenterol*. 1992;27(1).
14. Hébert M, Lesept F, Vivien D, Macrez R. The story of an exceptional serine protease, tissue-type plasminogen activator (tPA). *Rev Neurol (Paris)*. 2016;172(3):186-197. doi:10.1016/j.neurol.2015.10.002
15. Hayashi T, Kamogawa A, Ro S, et al. Plasma from patients with cirrhosis increases tissue plasminogen activator release from vascular endothelial cells in vitro. *Liver*. 1998;18(3):186-190. doi:10.1111/j.1600-0676.1998.tb00148.x
16. Leiper K, Croll A, Booth NA, Moore NR, Sinclair T, Bennett B. Tissue plasminogen activator, plasminogen activator inhibitors, and activator inhibitor complex in liver disease. *J Clin Pathol*. 1994;47:214-217.
17. Herrscher C, Roingard P, Blanchard E. Hepatitis B Virus Entry into Cells. *Cells*. 2020;9(6):1-15. doi:10.3390/cells9061486
18. Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. *Hepatoma Res*. 2016;2(7):163. doi:10.20517/2394-5079.2016.05
19. Tripathi N, Oy M. Hepatitis B. In: *StatPearls Publishing, Treasure Island (FL)*. ; 2022.

20. McCormick PA, Jalan R. Hepatic Cirrhosis. In: *Sherlock's Diseases of the Liver and Biliary System, Thirteenth Edition*. John Wiley & Sons Ltd; 2018:107-126.
21. Ivanova II. Liver cirrhosis: New concepts. *Scr Sci Medica*. 2016;48(2):9. doi:10.14748/ssm.v48i2.1481
22. A. Feitelson M. Pathogenesis of Hepatitis B Virus Associated Chronic Liver Disease. In: *Liver Cancer*. College of Science and Technology, Temple University; 2018. doi:10.5772/intechopen.79746
23. Suhail M, Abdel-Hafiz H, Ali A, et al. Potential mechanisms of hepatitis B virus induced liver injury. *World J Gastroenterol*. 2014;20(35):12462-12472. doi:10.3748/wjg.v20.i35.12462
24. Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: Molecular basis and therapeutic options. *World J Gastroenterol*. 2014;20(21):6457-6469. doi:10.3748/wjg.v20.i21.6457
25. Goldberg E, Chopra S. Cirrhosis in adults: Etiologies, clinical manifestations, and diagnosis. *UptoDate*. Published online 2017:1-29.
26. Tsoris A MC. Use Of The Child Pugh Score In Liver Disease. In: *StatPearls Publishing, Treasure Island (FL)*. ; 2022.
27. Ifeanyi OE, Chinedum OK, Uzoma OG, Ndidiamaka EG, Stella EI, Florence O. A REVIEW ON HEPATITIS AND HAEMOSTASIS. *Int J Compr Res Biol Sci*. 2018;5(2):24-46. doi:10.22192/ijcrbs.2018.05.02.003
28. Campbell S. Hemostasis. In: *Contemporary Practice in Clinical Chemistry*. INC; 2020:445-468. doi:10.1016/B978-0-12-815499-1.00026-0
29. Sherwood L. *Fisiologi Manusia*. 8th ed. EGC; 2014.
30. Fareed J, Iqbal O. Physiology of Hemostasis. In: *Anticoagulation and Hemostasis in Neurosurgery*. Springer International Publishing; 2016. doi:10.1007/978-3-319-27327-3

31. Moore AH. Thrombocytopenia in Cirrhosis: A Review of Pathophysiology and Management Options. *Clin Liver Dis.* 2019;14(5):183-186. doi:10.1002/cld.860
32. Wahyuni W, Novita D. HEMOSTATIC ABNORMALITIES IN PATIENT WITH LIVER CIRRHOSIS : A REVIEW. *J Kedokt DIPONEGORO.* 2022;11:226-230.
33. Charpentier V, Ives ST. Hyperfibrinolysis: An Uncommon Cause of Bleeding in Cirrhosis. *Am J Med.* 2022;135(1):53-54. doi:10.1016/j.amjmed.2021.06.045
34. Kodali S, Holmes CE, Tipirneni E, Cahill CR, Andrew MPH, Mary JG. Successful management of refractory bleeding in liver failure with tranexamic acid : Case report and literature review. 2019;(March):424-428. doi:10.1002/rth2.12203
35. Fauziyati. Hiperfibrinolisis Pada PAsien Sirosis Hati. *JKKI.* 2013;5:115-121.
36. Kujovich JL. Coagulopathy in liver disease: A balancing act. *Hematol (United States).* 2015;2015(1):243-249. doi:10.1182/asheducation-2015.1.243
37. Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. *J Thromb Haemost.* 2021;19(4):1116-1122. doi:10.1111/jth.15239
38. Lijnen HR, Rijken DC. t-Plasminogen Activator. *Handb Proteolytic Enzym.* 2013;3:2946-2952. doi:10.1016/B978-0-12-382219-2.00646-3
39. Hsiao Y, Zou T, Ling CC, Hu H, Tao XM, Song HY. Disruption of tissue-type plasminogen activator gene in mice aggravated liver fibrosis. *J Gastroenterol Hepatol.* 2008;23(7 PT2). doi:10.1111/j.1440-

1746.2007.05100.x

40. Zheng Z, Nakamura K, Gershbaum S, et al. Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. *J Clin Invest.* 2020;140(8):4348-4359. doi:10.1172/JCI135919
41. Ganti AK, Potti A, Yegnanarayan R. of Haemostasis and Plasminogen Activator Inhibitor-1 Levels in Acute Myocardial Infarction. *Pathophysiol Haemost Thromb.* 2002;32:80-84.
42. Yarmolinsky J, Bordin Barbieri N, Weinmann T, Ziegelmann PK, Duncan BB, Inês Schmidt M. Plasminogen activator inhibitor-1 and type 2 diabetes: A systematic review and meta-analysis of observational studies. *Sci Rep.* 2016;6(November 2015):1-13. doi:10.1038/srep17714
43. DIAPHARMA. Tissue plasminogen activator (tPA). doi:10.1007/978-3-319-12715-6_34
44. Liu M, Li L, Zhao J, Ungvari GS, dkk. Perbedaan gender dalam karakteristik demografi dan klinis pada pasien dengan penyakit hati terkait HBV di Tiongkok. *RekanJ.* 2022 Agustus 5;10:e13828. doi: 10.7717/peerj.13828. PMID: 35959480; PMCID: PMC9359133.
45. Anda H, Kong Y, Hou J, dkk. Jenis kelamin perempuan kehilangan efek perlindungan terhadap perkembangan penyakit pada pasien lanjut usia dengan hepatitis B kronis. *Sci Rep.* 2016 28 Nov;6:37498. doi: 10.1038/srep37498. PMID: 27892487; ID PMC: PMC5124962.
46. Zimmermann, H. W., Koch, A., Seidler, S., Trautwein, C., & Tacke, F. (2011). *Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.* *Liver International.* 2011. doi:10.1111/j.1478-3231.2011.02665.x